BRIEF-Allarity Therapeutics Doses Second Patient in Phase 2 Trial of Stenoparib for Advanced Ovarian Cancer

Reuters
27 Jun
BRIEF-Allarity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Doses Second Patient in Phase 2 Trial of Stenoparib for Advanced Ovarian Cancer

June 27 (Reuters) - Allarity Therapeutics Inc ALLR.O:

  • ALLARITY THERAPEUTICS ANNOUNCES DOSING OF SECOND PATIENT IN NEW PHASE 2 TRIAL OF STENOPARIB IN ADVANCED OVARIAN CANCER

Source text: ID:nGNXbD7lY9

Further company coverage: ALLR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10